| Compound | Class | 5α-R | AROM | 3-HSD | AAR | Estr | Prog | Oral | Hepat |
|---|---|---|---|---|---|---|---|---|---|
| Androstanolone | DHT | – | – | + | * | – | – | – | – |
| Boldenone | T | – | ± | – | ** | ± | – | – | – |
| Drostanolone | DHT | – | – | – | *** | – | – | – | – |
| Ethylestrenol | 19-NT; 17α-A | + (↓) | ± | – | *** | + | + | + | + |
| Fluoxymesterone | T; 17α-A | + (↑) | – | – | * | – | – | + | + |
| Mestanolone | DHT; 17α-A | – | – | + | * | – | – | + | + |
| Mesterolone | DHT | – | – | + | * | – | – | ± | – |
| Metandienone | T; 17α-A | – | ± | – | ** | + | – | + | + |
| Metenolone | DHT | – | – | – | ** | – | – | ± | – |
| Methyltestosterone | T; 17α-A | + (↑) | + | – | * | + | – | + | + |
| Nandrolone | 19-NT | + (↓) | ± | – | *** | ± | + | – | – |
| Norethandrolone | 19-NT; 17α-A | + (↓) | ± | – | *** | + | + | + | + |
| Oxandrolone | DHT; 17α-A | – | – | – | *** | – | – | + | ± |
| Oxymetholone | DHT; 17α-A | – | – | – | *** | + | – | + | + |
| Stanozolol | DHT; 17α-A | – | – | – | *** | – | – | + | + |
| Testosterone | T | + (↑) | + | – | * | + | – | ±a | – |
| Trenbolone | 19-NT | – | – | – | *** | – | + | – | – |
| Key: + = Yes. ± = Low. – = No. ↑ = Potentiated. ↓ = Inactivated. *** = High. ** = Moderate. * = Low. Abbreviations: 5α-R = Metabolized by 5α-reductase. AROM = Metabolized by aromatase. 3-HSD = Metabolized by 3α- and/or 3β-HSD. AAR = Anabolic-to-androgenic ratio (amount of anabolic ( myotrophic) effect relative to androgenic effect). Estr = Estrogenic. Prog = Progestogenic. Oral = Oral activity. Hepat = Hepatotoxicity. Footnotes: a = As testosterone undecanoate. Sources: [1] [2] [3] | |||||||||
References
- ^ Llewellyn, William (2011). Anabolics. Molecular Nutrition Llc. pp. 533–, 402–412, 460–467. ISBN 978-0-9828280-1-4.
- ^ Kicman, A T (2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521. doi: 10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.
- ^ Schänzer W (1996). "Metabolism of anabolic androgenic steroids" (PDF). Clin. Chem. 42 (7): 1001–20. doi: 10.1093/clinchem/42.7.1001. PMID 8674183.
| Compound | Class | 5α-R | AROM | 3-HSD | AAR | Estr | Prog | Oral | Hepat |
|---|---|---|---|---|---|---|---|---|---|
| Androstanolone | DHT | – | – | + | * | – | – | – | – |
| Boldenone | T | – | ± | – | ** | ± | – | – | – |
| Drostanolone | DHT | – | – | – | *** | – | – | – | – |
| Ethylestrenol | 19-NT; 17α-A | + (↓) | ± | – | *** | + | + | + | + |
| Fluoxymesterone | T; 17α-A | + (↑) | – | – | * | – | – | + | + |
| Mestanolone | DHT; 17α-A | – | – | + | * | – | – | + | + |
| Mesterolone | DHT | – | – | + | * | – | – | ± | – |
| Metandienone | T; 17α-A | – | ± | – | ** | + | – | + | + |
| Metenolone | DHT | – | – | – | ** | – | – | ± | – |
| Methyltestosterone | T; 17α-A | + (↑) | + | – | * | + | – | + | + |
| Nandrolone | 19-NT | + (↓) | ± | – | *** | ± | + | – | – |
| Norethandrolone | 19-NT; 17α-A | + (↓) | ± | – | *** | + | + | + | + |
| Oxandrolone | DHT; 17α-A | – | – | – | *** | – | – | + | ± |
| Oxymetholone | DHT; 17α-A | – | – | – | *** | + | – | + | + |
| Stanozolol | DHT; 17α-A | – | – | – | *** | – | – | + | + |
| Testosterone | T | + (↑) | + | – | * | + | – | ±a | – |
| Trenbolone | 19-NT | – | – | – | *** | – | + | – | – |
| Key: + = Yes. ± = Low. – = No. ↑ = Potentiated. ↓ = Inactivated. *** = High. ** = Moderate. * = Low. Abbreviations: 5α-R = Metabolized by 5α-reductase. AROM = Metabolized by aromatase. 3-HSD = Metabolized by 3α- and/or 3β-HSD. AAR = Anabolic-to-androgenic ratio (amount of anabolic ( myotrophic) effect relative to androgenic effect). Estr = Estrogenic. Prog = Progestogenic. Oral = Oral activity. Hepat = Hepatotoxicity. Footnotes: a = As testosterone undecanoate. Sources: [1] [2] [3] | |||||||||
References
- ^ Llewellyn, William (2011). Anabolics. Molecular Nutrition Llc. pp. 533–, 402–412, 460–467. ISBN 978-0-9828280-1-4.
- ^ Kicman, A T (2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521. doi: 10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.
- ^ Schänzer W (1996). "Metabolism of anabolic androgenic steroids" (PDF). Clin. Chem. 42 (7): 1001–20. doi: 10.1093/clinchem/42.7.1001. PMID 8674183.